Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck & Co. Inc. closed 42.70% short of its 52-week high of $134.63, which the company reached on June 25th.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck has traditionally eschewed large-scale M&A, but has been warming to the concept in recent years, with deals including its $11.5 billion takeover of Acceleron last year and its $2.75 billion ...

Bill Stone, Glenview Trust Company chief investment officer, mentioned his bullish take on Merck (NYSE:MRK) during a recent program on CNBC and explained the potential risks and rewards tied to ...

Get the detailed quarterly/annual income statement for Merck & Co., Inc. (MRK). Find out the revenue, expenses and profit or loss over the last fiscal year.

For a century, Corona has been synonymous with the beach, the outdoors, and embracing golden hour,” explains Clarissa Pantoja ...

Forbes contributors publish independent expert analyses and insights. Building a platform to do the job of 1 million analysts ...